FindTrial
Sign In

Serum concentrations of Dexmedetomidine in male patients undergoing kidney stone surgery after instilling Dexmedetomidine in urinary bladder and its relation with symptoms of Catheter related bladder discomfort.

Correlation of arterial concentrations of Dexmedetomidine with severity of Catheter Related Bladder Discomfort in male patients undergoing Percutaneous Nephrolithotomy after receiving Intravesical Dexmedetomidine. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057230
Enrollment
90
Registered
2023-09-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N200- Calculus of kidney

Interventions

Intervention1: Intravesical dexmedetomidine: 2.5 ug/kg dexmedetomidine in 100ml NS will be instilled through Foleyâ??s catheter and the catheter will be clamped for 30 minutes. Control Intervention1:

Sponsors

Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with renal stones about to undergo Percutaneous Nephrolithotomy

Exclusion criteria

Exclusion criteria: Patients with history of overactive bladder (frequency >3 times in the night or >8 times in 24 h), neurogenic bladder, morbid obesity, chemical substance abuse, chronic pain, and cardiovascular, hepatic or any psychiatric disease will be excluded.

Design outcomes

Primary

MeasureTime frame
Arterial concentration of dexmedetomidine in both the groupsTimepoint: At 30 minutes, 1, 2, 3, 6, 12 & 24 hours after administration of drug.—

Secondary

MeasureTime frame
Incidence of CRBD in each group.Timepoint: 3, 6, 12 & 24 hours after administration of drug.;Incidence of side effects like bradycardia, hypotensionTimepoint: 30 minutes, 1,2,3, hours after administration of surgery.—

Countries

India

Contacts

Public ContactDivya Srivastava

Sanjay Gandhi Post Graduate Institute of Medical Sciences

prash.outlaw@gmail.com07839098150

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026